Home / Health / GLP-1 Drugs Show Promise in Extending Mouse Lifespan
GLP-1 Drugs Show Promise in Extending Mouse Lifespan
4 Sep
Summary
- Semaglutide treatment extended lifespan in female mice.
- Drugs may temper harmful impacts of aging and reduce appetite.
- Further research needed to confirm human application and safety.
Recent research indicates that GLP-1 medications could offer benefits beyond weight management and diabetes treatment, potentially extending lifespan. A study conducted at the University of California, Berkeley, found that treating female mice with semaglutide, a GLP-1 receptor agonist, led to a prolonged life span.
The findings suggest that semaglutide may help slow aging by tempering its harmful impacts. This could open doors for applying GLP-1 medicines to healthy aging individuals, aiming to slow the aging process and extend life.
The study involved treating 20-month-old female mice daily with semaglutide. The treated mice not only lived longer but also exhibited reduced appetite and body weight. The GLP-1 treatment also reportedly improved physiological functions and attenuated hallmarks of aging.
Independent experts acknowledge the findings but advise tempered enthusiasm, noting that human application is significantly more complex. They emphasize the need for extensive safety evaluations, particularly for promoting longevity in healthy individuals. Some research also suggests these drugs may offer cardiovascular and anti-inflammatory benefits independent of weight loss.
